The initiation of patient enrolment in the STARS DAPT trial marks an important milestone for Abluminus np. While contemporary ...
Clinical Trials Arena on MSN
Axsome begins Phase III AXS-14 FORWARD trial for fibromyalgia management
Axsome Therapeutics has initiated the FORWARD Phase III trial evaluating AXS-14 for the management of fibromyalgia, with the ...
The KaiNETIC global Phase 3 clinical program includes three global, double-blind, randomized, placebo-controlled Phase 3 trials (KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3) to evaluate weekly ribupatide ...
Introduction The increasing incidence of type 2 diabetes mellitus (T2DM) among women of reproductive age poses significant health risks for both mothers and their fetuses. Optimising blood glucose ...
The sBLA is supported by data from the phase 3 SURPASS-ET trial, as well as confirmatory data from the phase 2b EXCEED-ET trial.
The FDA has accepted an investigational new drug application from a global biotechnology company for its investigational, ...
AXS-14 (esreboxetine) is a highly selective and potent norepinephrine reuptake inhibitor being developed for the management of fibromyalgia. Esreboxetine is the SS-enantiomer of racemic reboxetine.
Gedatolisib's NDA for advanced breast cancer treatment has been accepted by the FDA, with a priority review and a PDUFA date set for July 17, 2026. The drug is intended for HR+/HER2–, PIK3CA wild-type ...
SCOUT-HCM findings show mavacamten significantly reduces Valsalva LVOT gradient in adolescents with symptomatic oHCM.
(n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback